Cargando…

Abdominal Obesity: An Independent Influencing Factor of Visuospatial and Executive/Language Ability and the Serum Levels of Aβ40/Aβ42/Tau Protein

BACKGROUND: Although obesity affects human health and cognitive function, the influence of abdominal obesity on cognitive function is still unclear. METHODS: The MoCA scale was used to evaluate the overall cognitive function and the function of each subitem of 196 subjects, as well as the SDMT and T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Xin, Zhong, Yun, Zhang, Lingling, Li, Jiaqi, Xie, Fei, Zhang, Zhiyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993554/ https://www.ncbi.nlm.nih.gov/pubmed/35401883 http://dx.doi.org/10.1155/2022/3622149

Ejemplares similares

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Visuospatial Working Memory Mediates the Relationship Between Executive Functioning and Spatial Ability
por: Wang, Lu, et al.
Publicado: (2018)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Corrigendum: Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects
por: Lue, Lih-Fen, et al.
Publicado: (2019)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Total Aβ(42)/Aβ(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
por: Doecke, James D., et al.
Publicado: (2020)

Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
por: Wang, Li, et al.
Publicado: (2021)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

Impact of Aβ40 and Aβ42 Fibrils on the Transcriptome of Primary Astrocytes and Microglia
por: Zhu, Xiaoyue, et al.
Publicado: (2022)

Endocytic uptake of monomeric amyloid-β peptides is clathrin- and dynamin-independent and results in selective accumulation of Aβ(1–42) compared to Aβ(1–40)
por: Wesén, Emelie, et al.
Publicado: (2017)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
por: Kwak, Sang Su, et al.
Publicado: (2020)

Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
por: Hossain, Iftakher, et al.
Publicado: (2020)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

Dynamic Blood Concentrations of Aβ(1–40) and Aβ(1–42) in Alzheimer’s Disease
por: Yang, Yuan-Han, et al.
Publicado: (2020)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

The Involvement of Aβ42 and Tau in Nucleolar and Protein Synthesis Machinery Dysfunction
por: Maina, Mahmoud B., et al.
Publicado: (2018)

Neurodegenerative disease biomarkers Aβ(1–40), Aβ(1–42), tau, and p‐tau(181) in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy
por: Chen, Jason A., et al.
Publicado: (2018)

Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ(40/42) and Tau Hyperphosphorylation
por: Das, Tushar Kanti, et al.
Publicado: (2019)

Cell Line Specific Modulation of Extracellular Aβ(42) by Hsp40
por: Carnini, Anna, et al.
Publicado: (2012)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Self-Assembly of Aβ40, Aβ42 and Aβ43 Peptides in Aqueous Mixtures of Fluorinated Alcohols
por: Pachahara, Sanjai Kumar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5l84hirn1hb2b9m5g7qp5es00b